November 11, 2003
Stereotactic Lung Cancer Study Produces Positive Initial Results
INDIANAPOLIS - The initial phase of a clinical trial for treatment of
early stage lung cancer has produced positive results, according to an
article appearing Nov. 11 in the journal Chest.
Researchers at Indiana University School of Medicine reported that the
results of the extracranial stereotactic radioablation Phase I study for
non-small cell lung cancer led the group to continue with the second phase
of the clinical trial.
The initial phase tested the toxicity of increasingly large doses of
radiation precisely focused on the lung tumor. Enrollment in the trial
began in February 2000 and 37 patients participated. Researchers report
that surprisingly high doses of radiation were tolerated and 87 percent
of patients had positive tumor response. Only six patients had local recurrence
of cancer, all treated at the lower dose levels used at the onset of the
trial. Local recurrence has not been observed to date at the highest levels.
Patients enrolled in the Phase I study had to have stage I non-small
cell lung cancer that was medically inoperable because of extenuating
health problems. Non-small cell lung cancer accounts for 80 percent of
all lung cancers and is the leading cause of cancer-related fatalities
in the United States. In the U.S., 170,000 new cases of lung cancer are
diagnosed each year and there are 157,000 deaths caused by the disease.
"Lung cancer patients frequently have other health problems such
as emphysema or heart disease that makes them a bad risk for the standard
surgical therapy for their disease," said Robert Timmerman, M.D.,
associate professor of radiation oncology and the principal author of
the article.
Using a painless, minimally invasive therapy, Timmerman and his IU colleagues
used 3-D imaging and stereotactic body mapping to precisely target the
tumor down to a millimeter so that healthy tissue was spared the intensity
of the photon radiation. Stereotactic mapping utilizes a specially designed,
lightweight body frame that limits mobility to ensure the precision of
photon beams aimed at the tumor.
"The results of the first phase were very encouraging and somewhat
surprising," Dr. Timmerman said. "We thought patients would
only tolerate lower doses of radiation since they were frail to begin
with. To our delight, we were able to increase dose levels without prohibitive
toxicity. In the end, the therapy should be extremely potent against that
cancer."
Early stage lunch cancer traditionally is treated with surgery, conventional
radiation, or both. There is a 60 percent to 70 percent cure rate for
early stage lung cancer in patients undergoing surgery and a 20 percent
to 30 percent cure rate for those treated with conventional radiation,
which involves five weeks to six weeks of daily radiation treatments.
The stereotactic treatment plan involved only three outpatient treatments
but at a much higher dose rate than conventional radiation.
The Phase I study was completed in December 2001. Phase II of the study began in January 2002 and 48 patients have been enrolled. This second phase seeks to quantify beneficial aspects of the therapy such as survival and local disease control when radiation is delivered at the highest dose levels.
Individuals interested in enrolling in the study or those wanting additional
information may contact Tia Whitford, R.N., at 317-278-7267.
"This study holds promise for a group of patients who had few good
options," says Dr. Timmerman. "It is hoped the stereotactic
treatments not only will give medically frail patients with early stage
lung cancer a choice but perhaps someday be another option for a larger
spectrum of lung cancer patients."
# # #
Media Contact: Mary Hardin
317-274-7722
mhardin@iupui.edu
INDIANA UNIVERSITY
SCHOOL OF MEDICINE
A STATEWIDE
RESOURCE
Phone
317 274 7722
Fax
317 278 8722